These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2810822)

  • 1. Cytotoxic activity of various LAK cells against autologous lung cancer, K-562 and Daudi cells.
    Kimura H; Yamaguchi Y
    Jpn J Clin Oncol; 1989 Sep; 19(3):222-8. PubMed ID: 2810822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The characteristic of lymphokine-activated killer cells induced from tumor draining lymph-node cell].
    Meng YG; Fu CY; Wang YZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):535-7, 574. PubMed ID: 7835130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y; Watanabe S; Kodama T
    Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
    Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
    No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer (LAK) cell purging of bone marrow.
    Cramer DV; Long GS
    Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
    Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
    Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
    Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
    Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cytotoxicity to autologous tumor cells by the regional lymph node cells of patients with primary lung cancer.
    Kadoyama C; Kimura H; Yamaguchi Y
    Jpn J Clin Oncol; 1987 Mar; 17(1):29-39. PubMed ID: 2951535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
    Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.
    Zambello R; Trentin L; Feruglio C; Bulian P; Masciarelli M; Cipriani A; Agostini C; Semenzato G
    Cancer Res; 1990 Mar; 50(6):1768-73. PubMed ID: 2106387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
    Guo Y; Xing Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.